These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9716616)

  • 1. Leukemic transformation in polycythemia Vera. MPD(UK) Study Group.
    Pearson TC; Green AR; Reilly JT; Harrisoni G
    Blood; 1998 Sep; 92(5):1837-8. PubMed ID: 9716616
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
    Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
    Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
    Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
    Najean Y
    Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
    Boivin P
    Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of polycythaemia with pipobroman].
    Perreau-Boutet MC; Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Nouv Presse Med; 1982 Sep; 11(34):2549-53. PubMed ID: 7133977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
    Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
    J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
    Ellis AK; Lee DH
    Am J Hematol; 2002 Nov; 71(3):237-8. PubMed ID: 12410589
    [No Abstract]   [Full Text] [Related]  

  • 10. [Hydroxyurea induced-leg ulcer in polycythemia vera].
    Khaled A; El Guellali N; Aissaoui L; Robbana F; Ezzine N; Fazaa B; Kamoun MR
    Tunis Med; 2011 Mar; 89(3):292-4. PubMed ID: 21387237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aplastic anemia responsive to cyclosporine complicating the evolution of polycythemia vera.
    Bouscary D; Jondeau K; Viguié F; Zompi S; Fontenay-Roupie M; Quarre MC; Vassilief D; Dreyfus F; Casadevall N
    Leuk Lymphoma; 1999 May; 33(5-6):607-11. PubMed ID: 10342591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea and sickle cell crisis.
    Silver RT
    N Engl J Med; 1995 Oct; 333(15):1008-9. PubMed ID: 7666903
    [No Abstract]   [Full Text] [Related]  

  • 13. Management of polycythemia vera with hydroxyurea.
    Tatarsky I; Sharon R
    Semin Hematol; 1997 Jan; 34(1):24-8. PubMed ID: 9025159
    [No Abstract]   [Full Text] [Related]  

  • 14. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
    Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17.
    Tóthová E; Fricová M; Stecová N; Hlebasková M; Kafková A; Raffac S; Guman T; Svorcová E; Nebesnáková E
    Neoplasma; 2001; 48(5):389-92. PubMed ID: 11845984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
    Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
    Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antineutrophil cytoplasmic antibody-associated vasculitis in a patient with polycythemia vera after long-term hydroxyurea treatment.
    Su L; Zheng J; Xiu L; Li J; Ding M; He W
    Leuk Lymphoma; 2011 Nov; 52(11):2193-4. PubMed ID: 21718133
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of two antineoplastic agents, PIPOBROMAN (vercyte) and thioguanine.
    JAMA; 1967 May; 200(7):619-20. PubMed ID: 5228673
    [No Abstract]   [Full Text] [Related]  

  • 19. Pipobroman therapy of polycythemia vera.
    Najman A; Stachowiak J; Parlier Y; Gorin NC; Duhamel G
    Blood; 1982 May; 59(5):890-4. PubMed ID: 7074217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
    Passamonti F; Lazzarino M
    Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.